Renal Cell Carcinoma
📧 Sign up to get email alerts when something new happens for Renal Cell Carcinoma.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2025-03-03EMA Authorised: Torisel (temsirolimus) — Pfizer Europe MA EEIG
EMA authorised temsirolimus (Torisel) for renal cell carcinoma and mantle cell lymphoma in the EU, with Pfizer Europe MA EEIG as the marketi…
-
CLINICAL_TRIALS trial_result · 2025-02-28Clinical Trial Update: Software Monitoring of Treatment Related Toxicities in Advanced Renal Cell Carcinoma [NA]
This entry documents the completion of a University of Rochester clinical trial evaluating software-based monitoring of treatment-related to…
-
CLINICAL_TRIALS research · 2025-02-28Clinical Trial Update: CD70-targeted immunoPET Imaging of Malignant Cancers [NA]
A clinical trial evaluating CD70-targeted immunoPET imaging in multiple cancers is currently recruiting, including renal cell carcinoma, dif…
-
CLINICAL_TRIALS trial_result · 2025-02-26Clinical Trial Update: Preliminary Evaluation of Uptake of [68Ga]P16-093 in Metastatic Prostate and Renal Cancer [Phase 1]
Phase 1 trial completed evaluating uptake of the radiotracer [68Ga]P16-093 in metastatic prostate cancer and metastatic renal cell carcinoma…
-
CLINICAL_TRIALS research · 2025-02-25Clinical Trial Update: Comparison Between HUGO RAS Robotic Platform and Da Vinci Robotic Platform [NA]
A clinical trial comparing the HUGO RAS robotic platform with the Da Vinci robotic platform in patients with prostate cancer and renal cell …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-02-24Clinical Trial Update: First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients with Selected Advanced And/or Metastatic Solid Tumours [Phase 1]
Phase 1 first-in-human study to evaluate safety, tolerability and antineoplastic activity of OATD-02 in patients with selected advanced/meta…
-
CLINICAL_TRIALS research · 2025-02-20Clinical Trial Update: SABR for Renal Tumors [NA]
A clinical trial evaluating stereotactic ablative radiotherapy (SABR) for renal tumors is currently recruiting in Toronto, Canada.
-
CLINICAL_TRIALS trial_result · 2025-02-18Clinical Trial Update: Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors [Phase 1]
Phase 1 interventional trial evaluating INCB 99280 in combination with ipilimumab in select solid tumors has been terminated. The study, spo…
-
CLINICAL_TRIALS trial_result · 2025-02-17Clinical Trial Update: Percutaneous Tumor Ablation Vs Partial Nephrectomy for Small Renal Mass: the Impact of Histologic Variant and Tumor Size
A completed clinical trial comparing percutaneous tumor ablation with partial nephrectomy for small renal masses, assessing how histologic v…
-
CLINICAL_TRIALS trial_result · 2025-02-14Clinical Trial Update: A Study of Nivolumab Plus Ipilimumab in Participants With Renal Cell Cancer in the Real World Setting in Japan
This is a completed real-world clinical trial evaluating the combination of nivolumab and ipilimumab for advanced or metastatic renal cell c…
-
FDA approval · 2025-02-14FDA Approved: SUNITINIB MALATE — Original Application (Novadoz Pharmaceuticals LLC)
The FDA approved an original generic application for sunitinib malate from Novadoz Pharmaceuticals LLC. This approval provides a generic opt…
-
CLINICAL_TRIALS trial_result · 2025-02-12Clinical Trial Update: Clinical-pathological Characterization and Outcomes of Renal Cell Carcinoma in Latin American
A completed Latin American multicenter study characterizes clinicopathological features and outcomes of renal cell carcinoma.
-
CLINICAL_TRIALS research · 2025-02-12Clinical Trial Update: Impact of Chronic Renal Failure on Plasma Exposure of Kinase Inhibitors in Patients Treated for Metastatic Kidney Cancer [NA]
This clinical trial update examines how chronic renal failure may influence plasma exposure of kinase inhibitors in patients with metastatic…
-
FDA approval · 2025-02-11FDA Approved: TEMSIROLIMUS — Supplemental Application (Accord Healthcare Inc.)
FDA approved Accord Healthcare's supplemental application for temsirolimus, bringing a generic version to the market. The approval covers te…
-
CLINICAL_TRIALS trial_result · 2025-02-06Clinical Trial Update: High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma [Phase 2]
Phase 2 trial evaluating high-dose interleukin-2 in combination with an anti-PD-1 therapy to overcome resistance in metastatic melanoma and …
-
CLINICAL_TRIALS trial_result · 2025-02-03Clinical Trial Update: Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers [Phase 1]
Phase 1 study of cosibelimab (CK-301) as a single-agent therapy in adults with advanced cancers; the trial status is active but not recruiti…
-
FDA approval · 2025-01-30FDA Approved: FOTIVDA — Supplemental Application (AVEO Pharmaceuticals, Inc.)
FDA approved a supplemental application for FOTIVDA (tivozanib) filed by AVEO Pharmaceuticals, Inc.
-
CLINICAL_TRIALS trial_result · 2025-01-30Clinical Trial Update: Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer [EARLY_Phase 1]
This early-phase 1 trial update reports completion of a study evaluating daratumumab in patients with muscle-invasive bladder cancer and met…
-
CLINICAL_TRIALS research · 2025-01-24Clinical Trial Update: Prehabilitation Prior to Surgery for Kidney Tumors [NA]
A clinical trial sponsored by Herlev and Gentofte Hospital is investigating prehabilitation before surgery for kidney tumors and is currentl…
-
EMA approval · 2025-01-22EMA Authorised: Inlyta (axitinib) — Pfizer Europe MA EEIG
EU authorisation granted for Inlyta (axitinib) for renal cell carcinoma. The marketing authorisation holder is Pfizer Europe MA EEIG.
-
CLINICAL_TRIALS trial_result · 2025-01-20Clinical Trial Update: Treatment Patterns and Clinical Outcomes Among Patients With Advanced Renal Cell Carcinoma (aRCC) Receiving Systemic First-line (1st Line) Anti-cancer Treatment Under Daily Routine in Germany: Retrospective Medical Chart Review (RENALISTIC Study).
A retrospective chart review (RENALISTIC) evaluated first-line systemic treatment patterns and clinical outcomes in German patients with adv…
-
CLINICAL_TRIALS research · 2025-01-14Clinical Trial Update: Study of the Prognostic Impact of CD44 on Renal Cell Carcinoma
This clinical trial investigates the prognostic impact of CD44 in renal cell carcinoma and is currently not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2025-01-13Clinical Trial Update: Radiotherapy As an Immunological Booster in Patients with Metastatic Melanoma or Renal Cell Carcinoma Treated with High-dose Interleukin-2 [Phase 2]
Phase 2 trial evaluating radiotherapy as an immunological booster in patients with metastatic melanoma or metastatic renal cell carcinoma tr…
-
CLINICAL_TRIALS research · 2025-01-10Clinical Trial Update: A Study Evaluating the Value of 68Ga-NOTA-RCCB6 PET Imaging for Targeting CD70 in the Clinical Staging, Therapeutic Evaluation, and Restaging of Renal Cell Carcinoma, and Comparing It with 68Ga-PSMA PET/CT Imaging [NA]
A ClinicalTrials.gov study at Xijing Hospital is evaluating 68Ga-NOTA-RCCB6 PET imaging for staging, therapeutic evaluation, and restaging o…
-
CLINICAL_TRIALS research · 2025-01-10Clinical Trial Update: Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
This clinical trial update notes a study analyzing primary and metastatic tumors in patients with renal cell carcinoma and urothelial carcin…